Practical Guidance on New Immuno-Oncology Strategies for Renal Cell and Urothelial Carcinoma
The goal of this activity is to increase participants’ knowledge of immune checkpoint inhibitors and improve competence and performance in the safe and effective integration of these agents in the treatment of renal cell carcinoma and urothelial carcinoma.
Jointly provided by National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.
This program is intended for physicians, nurses, and other healthcare providers who care for patients with renal cell carcinoma or bladder cancer.
Upon completion of this activity, participants should be able to:
- Gain insight on the mechanism of action and rationale for using immune checkpoint inhibitors to treat patients with advanced bladder cancer and renal cell carcinoma
- Evaluate the available data and recommendations in the NCCN Guidelines® on different checkpoint inhibitors to guide therapy decisions for patients with bladder cancer and renal cell carcinoma
- Describe challenges faced by the multidisciplinary care teams when planning therapeutic strategies for patients with genitourinary cancers
- Compare the current understanding on the benefits of monotherapy and combination checkpoint inhibitor therapies in the treatment of first line, second line, and subsequent lines of therapy for bladder cancer and renal cell carcinoma
- Recognize response patterns specific to immunotherapies, including pseudoprogression and atypical response kinetics
- Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
M. Dror Michaelson, MD, PhD
Clinical Director, Genitourinary Cancer Center
Associate Professor of Medicine
Massachusetts General Hospital Cancer Center
Sumanta Kumar Pal, MD
Associate Clinical Professor
Department of Medical Oncology and Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.
The faculty and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
M. Dror Michaelson, MD, PhD, has disclosed that he has served on advisory boards for Exelixis, Novartis, and Pfizer and that his spouse is an employee of Jounce Therapeutics.
Sumanta Kumar Pal, MD, has disclosed that he has received consulting fees from Aveo Oncology, Eisai, Exelixis, Genentech, Ipsen, Novartis, and Pfizer.
Elizabeth R. Plimack, MD, MS, has disclosed that she has served as a scientific advisor or consultant for AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, Horizon Pharma, Inovio, Lilly, Novartis, Pfizer, and Roche and has received funds for research support or clinical trials from Acceleron, Agensys, AstraZeneca, Bristol-Myers Squibb, Merck, Peloton, and Pfizer.
The activity planning staff listed below has no relevant financial relationships to disclose:
CCO: Kristen Rosenthal, PhD; Rachael M. Andrie, PhD; Krista Marcello; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Karen Kanefield; Kristin Kline Hasson; Joan S. McClure, MS; Lisa Perfidio; Kathy Smith
The NCCN clinical information team listed below, who have reviewed content, have no relevant financial relationships to disclose:
Lisa Gurski, PhD; Rashmi Kumar, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of NCCN and Clinical Care Options, LLC. NCCN is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. NCCN designates this educational activity for a maximum of 2.0 contact hours.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC contact hours
- 2.00 Participation